What is the revenue and EPS growth rate for Neogen year over year?

Did Neogen beat or miss consensus estimates last quarter?

What is Neogen's latest dividend and current dividend yield?

What is the market's earnings forecast for Neogen next quarter?

What factors drove the changes in Neogen's revenue and profit?

What were the key takeaways from Neogen’s earnings call?

What were the key takeaways from Neogen's earnings call?

What does Neogen do and what are its main business segments?

- **Revenue Recovery**: Q2 core growth of 2.9% marks first positive quarter in 4, driven by Food Safety (4.1% growth) and cost savings.
- **Margin Expansion**: Adjusted EBITDA margin jumps 470 bps to 21.7%, supported by gross margin improvement to 47.5%.
- **Strategic Moves**: $20M cost cuts, leadership hires, and Petrifilm integration on track for Q2 FY27.
- **Guidance Uptick**: FY26 EBITDA raised to $175M, reflecting Q2 outperformance but cautious on macro challenges.
- **Key Risks**: Lingering food production weakness and new team execution uncertainty.

**【CEO Summary Section】**
- CEO highlights return to positive core growth (2.9% YoY) and adjusted EBITDA margin improvement of 470 basis points to 21.7%.
- Announces $20 million annualized cost savings and strategic leadership hires (CFO, CCO, GM Food Safety).
- Emphasizes solutions-based selling in Food Safety, targeting 75%+ multi-category customers.
- Sample collection product line optimization underway, expected to contribute positively to gross profit in H2 FY26.
- Petrifilm integration on track for Q2 FY27, with production testing and validation progressing well.
- Genomics divestiture expected to close in Q4 FY26, supporting balance sheet deleveraging.

**【CFO Financial Commentary】**
- Q2 revenue of $224.7 million, driven by 4.1% growth in Food Safety (pathogens, allergens) and flat Animal Safety (biosecurity gains offset by instrument declines).
- Gross margin improves to 47.5% (50.3% ex-integration costs), up 210 bps vs. Q1, due to volume and tariff reductions.
- Adjusted EBITDA of $48.7 million reflects $20.9 million free cash flow improvement vs. Q1, with CapEx expected to normalize at 3-4% of revenue.
- Updated FY26 guidance: $845-855 million revenue (+1.3-3.3% YoY) and $175 million EBITDA, with cautious H2 outlook due to macro challenges.

**【Q&A Highlights】**
- **Management Transition**: New executives (e.g., CCO Joe Freels) are "hitting the ground running," with weekly forecast reviews driving commercial discipline.
- **Sample Collection Margins**: Q2 non-GAAP impact reduced to $3 million (from $10M in Q4 FY25), expected to turn positive in H2.
- **Petrifilm Manufacturing**: 17 SKUs in validation phase, with successful plate production testing; on track for Q2 FY27 launch.
- **Growth Drivers**: Volume growth in indicator testing (sample collection, pathogens) and culture media, offsetting macro food production weakness.
- **Customer Dynamics**: Strong customer retention despite supply chain issues, with 75%+ multi-category Food Safety customers.


Neogen Corporation(NEOG)-20260108-2026 Q2 Earnings call transcript

- **Cost Restructuring Success**: $20M annualized savings from 10% headcount reduction, with $12M FY26 benefit.
- **Petrifilm Recovery**: U.S. sellout growth signals underlying demand, despite Q1 revenue decline.
- **Cash Flow Improvement**: Free cash flow outflow reduced by $43M YoY, driven by working capital efficiency.
- **Strategic Focus**: 2026 priorities include food safety market share gain, sample collection productivity, and Petrifilm production transition.
- **Margin Expansion Path**: Targeting EBITDA margin expansion through OpEx savings and operational efficiency gains.

**【Management Opening Remarks】**
- New CEO Mikhael Nassif emphasized Neogen's leadership in food and animal safety, while acknowledging past execution challenges. 
- CFO Dave Naemura highlighted Q1 revenue of $209M (flat YoY core basis) and reaffirmed full-year guidance despite headwinds in sample collection and Petrifilm.

**【CEO Strategic Priorities】**
- **Cost Restructuring**: 10% headcount reduction ($20M annualized savings) to align costs with current revenue levels.
- **Top-Line Growth**: Targeting U.S. food safety market share gains, with Petrifilm U.S. sellout growth despite Q1 revenue decline.
- **Operational Efficiency**: S&OP process improvements to reduce inventory write-offs and streamline supply chain.
- **Innovation Reboot**: Focused R&D pipeline on high-impact projects, including Petrifilm production transfer to U.S. by Q2 2026.

**【CFO Financial Highlights】**
- **Revenue**: $209M (Q1 FY26), +0.3% core YoY. Food Safety segment (-4.6% YoY) offset by Animal Safety (+5.8% YoY).
- **Margins**: Adjusted EBITDA $35.5M (17% margin), impacted by sample collection inefficiencies and tariffs.
- **Cash Flow**: Free cash flow outflow of $13M (vs. -$56M prior year), driven by lower CapEx and working capital improvements.
- **Debt**: $800M gross debt, with $115M proceeds from C&D divestiture reducing interest costs by ~$6M/year.

**【Q&A Key Themes】**
- **Share Regain Strategy**: CEO Nassif outlined commercial excellence initiatives, including targeted price increases and channel optimization.
- **Margin Outlook**: CFO Naemura expects EBITDA margin expansion through Q4, driven by OpEx savings ($12M FY26) and sample collection productivity gains.
- **Petrifilm Confidence**: CEO highlighted strong U.S. sellout trends and on-track production transfer timeline, targeting incremental margin improvement.
- **Genomics Sale Progress**: Ongoing discussions, with potential impact on FY26 guidance if finalized.


Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript

- **Market Challenges**: Food Safety growth constrained to low single digits due to inflation and production declines; Animal Safety in cyclical trough.
- **Regulatory Tailwinds**: USDA's focus on Listeria and Salmonella testing (200% increase in samples) supports pathogen detection growth.
- **Financial Performance**: Q4 revenue $225M (-2.9% core), EBITDA $41M (18% margin). 2026 guidance: $820M-$840M revenue, $165M-$175M EBITDA.
- **Strategic Actions**: $10M annualized tariff impact, $598M goodwill impairment, Petrifilm production delays, and genomics divestiture.
- **Key Risks**: Sample collection inefficiencies, trade uncertainty, and macroeconomic softness.

**【CEO Summary Section】**
- **Market Conditions**: Food Safety segment faced challenges due to consumer inflation and production volume declines, with core revenue growth constrained to low single digits. USDA's focus on Listeria and Salmonella testing (e.g., 200% increase in Listeria samples tested in 2025) provides regulatory tailwinds. Animal Safety segment in cyclical trough due to cattle herd decline and cautious distributor behavior.
- **New Product Launches**: Launched Listeria Right Now assay for MDS platform, enhancing pathogen detection capabilities. Genomics segment saw sequential improvement but remains in divestiture process.
- **Strategic Actions**: Announced $10M annualized tariff impact, Petrifilm production transition delays, and $598M goodwill impairment related to 3M Food Safety acquisition. Targeted improvement plan focuses on cost control, inventory management, and operational efficiency.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Revenue $225M (-2.9% YoY core), Food Safety segment $162M (-3% YoY), Animal Safety $64M (-6.7% YoY core). Gross margin 41.2% (impacted by inefficiencies, tariffs). Adjusted EBITDA $41M (18% margin), down due to lower volume and inefficiencies.
- **Outlook 2026**: Revenue $820M-$840M (excluding divested businesses), EBITDA $165M-$175M. Anticipate margin improvement in H2 driven by sample collection efficiency gains and lower inventory write-offs. Free cash flow expected to turn positive with reduced CapEx ($50M vs. $64M in 2025).
- **Balance Sheet**: Debt $900M, cash $129M. Divestiture of cleaners/disinfectants business (net proceeds $115M) to reduce leverage by 0.4x.

**【Q&A Key Highlights】**
- **Tariff Impact**: CFO clarified $10M annualized headwind for 2026, up from prior $5M estimate, due to delayed mitigation and competitor actions.
- **Petrifilm Transition**: Test production expected to begin soon, with 17 SKUs to be certified over 4-5 quarters. Inefficiencies in sample collection (manual labor, scrap) will persist but improve gradually.
- **Genomics Divestiture**: Sequential improvement in bovine business, but overall segment expected to decline in 2026 as focus shifts to core markets.
- **Management Transition**: Incoming CEO Mike will focus on operational rigor and execution, with no immediate changes to strategic direction.


Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript

- **CEO Transition**: John Adent stepping down, with succession search underway amid macro uncertainty.
- **Revenue Challenges**: Q3 $6M shortfall due to tariff fears, China weakness, and sample collection delays.
- **Food Safety Resilience**: 7% core growth (excl. sample collection) vs. historical 15% growth rates.
- **Tariff Mitigation**: $30M annualized exposure, 2/3 from China; 40% of China sales from U.S. manufacturing.
- **Balance Sheet Strength**: $900M debt refinanced to 6.5% coupon, 61% fixed-rate; $128M cash on hand.
- **Strategic Actions**: $10M+ annual savings from sample collection restructuring; $100M+ Petrifilm transition investment.

**【CEO Summary Section】**
- CEO John Adent announced his planned departure, emphasizing the company's strong position post-acquisition integration.
- Highlighted macroeconomic challenges: U.S. government spending cuts, tariffs, and global trade uncertainty impacting revenue by $6M in Q3.
- Food Safety segment core growth of 7% (excluding sample collection) reflects resilience despite macro headwinds.
- Sample collection production restored to prior levels, but demand recovery expected over coming quarters.
- Refinanced $550M Term Loan A to extend maturity by 2.5 years, saving 60bps in interest costs.
- Focus on cost alignment with revenue and balance sheet flexibility through debt repayment.

**【CFO Financial Commentary】**
- Q3 revenue $221M, with core growth of 0.2% (excluding FX, acquisitions, and discont. lines), offset by 3.1% FX headwind.
- Food Safety segment: $153M, down 3.2% YoY, driven by sample collection delays and FX.
- Animal Safety: $68M, down 2.6% YoY, with genomics decline offset by small animal supplements growth.
- Global Genomics: mid-single-digit core decline, with focus on profitable bovine business.
- Gross margin 49.9%, down 120bps YoY due to lower revenue and integration costs.
- Adjusted EBITDA $49M (22% margin), flat QoQ but down 10% YoY.
- Free cash flow outflow $14M, improved $49M YoY; net debt $900M, 61% fixed-rate.
- Updated FY25 guidance: revenue $895M (down $20M), adj. EBITDA $195M (down $15M).

**【Q&A Key Highlights】**
- **Tariff Impact**: $30M annualized exposure, 2/3 from China; 40% of China sales from U.S. manufacturing. Potential to pass 2/3 of costs through pricing.
- **Food Safety Resilience**: 7% core growth (excl. sample collection) vs. 15Q historical growth rates; proxy for global food production declined 70-80bps QoQ.
- **Petrifilm Transition**: 17 SKUs to migrate 1 at a time; test production Q4 2025, full transition by Q4 2026 with $10M+ annualized savings.
- **Cost Management**: $10M+ annual savings from sample collection restructuring; $100M+ CapEx FY26 for Petrifilm, declining to $30M+ FY27.
- **Balance Sheet**: $128M cash, $100M revolver draw for portfolio actions; targeting net leverage <2x by FY27.


Neogen (NEOG)-9 Apr 25-2025 Q3 Earnings call transcript

- **Food Safety Growth**: Core +4% YoY, with Petrifilm expansion targeting 20-hour results.
- **Animal Safety Recovery**: +3.2% YoY, offset by genomics decline as companion animal market weakens.
- **FX Headwind**: FY25 revenue reduced $25M midpoint, EPS down $0.04.
- **Cost Savings**: Freight/distribution improvements to enhance Q2+ margins.
- **Regulatory Tailwind**: USDA initiatives align with Neogen's portfolio, supporting long-term growth.

**【CEO Business Overview】**
- **Food Safety Segment**: Core revenue grew 4% YoY, driven by biosecurity and bacterial sanitation products. Sample collection production ramp-up is expected to reach prior levels by Q3 2025, with Petrifilm expansion targeting 20-hour results for Bacillus cereus.
- **Animal Safety Segment**: Core revenue increased 3.2% YoY, with growth in biosecurity and biologics. Genomics revenue declined mid-single digits due to companion animal market weakness, offset by cattle growth.
- **Regulatory Tailwinds**: USDA's expanded Salmonella framework and Listeria monitoring initiatives align with Neogen's portfolio, supporting long-term demand.

**【CFO Financial Highlights】**
- **Q2 2025 Results**: Revenue $231M (-2.5% YoY due to FX). Adjusted EBITDA $51M (22.2% margin). GAAP net loss due to $135M goodwill impairment from 3M Food Safety integration.
- **Guidance Update**: FY25 revenue now $900-920M (down $25M midpoint) due to FX (-2.5% headwind), genomics restructuring, and sample collection delay. Adjusted EBITDA $185-195M (down $10M midpoint).
- **Cost Actions**: Freight/distribution improvements expected to enhance Q2+ margins, with free cash flow positive for FY25.

**【Q&A Key Takeaways】**
- **FX Impact**: $2.5M/Q2 revenue loss, $0.01/Q2 EPS dilution. FY25 FX headwind ~$10M.
- **Sample Collection Recovery**: Q2 loss ~$6M, expected to normalize by Q3. Full recovery by Q4 with share regain.
- **Genomics Restructuring**: Companion animal exit reduces FY25 revenue by ~$5M, focusing on high-margin cattle genomics.
- **Regulatory Outlook**: USDA's Listeria guidelines and Salmonella framework may drive incremental testing demand, benefiting Neogen's broad portfolio.


Actual											0.115	0.155	0.15	0.15	0.125	0.15	0.16	0.1	0.05	0.14	0.05	-0.19	0.04	0.03	0.01	-0.02	-0.01	-0.02	-0.06	-2.1	-0.05	-2.82	0.04	0.1
Forecast											0.135	0.1488	0.1375	0.1567	0.1283	0.1383	0.16	0.17	0.12	0.115	0.105	-0.08	-0.015	0.0133	0.025	0.025	0.015	-0.01	-0.0333	-0.0125	-0.0175	-0.0475	-0.074	0.0625
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14.81%	+4.17%	+9.09%	-4.28%	-2.57%	+8.46%	0.00%	-41.18%	-58.33%	+21.74%	-52.38%	-137.50%	+366.67%	+125.56%	-60.00%	-180.00%	-166.67%	-100.00%	-80.18%	-16700.00%	-185.71%	-5836.84%	+154.05%	+60.00%

NEOG

NEOG fundamentals

NEOG Q2 2026 Earnings

Earnings Call

You can ask Aime

NEOG

NEOG fundamentals

NEOG Q2 2026 Earnings

Earnings Call

NEOG Earnings Call Summary for Q2/20268:00 AM on Jan 8, 2026

NEOG Earnings Call Summary for Q1/20268:00 AM on Oct 9, 2025

NEOG Earnings Call Summary for Q4/20258:00 AM on Jul 29, 2025

NEOG Earnings Call Summary for Q3/20258:00 AM on Apr 9, 2025

NEOG Earnings Call Summary for Q2/20258:00 AM on Jan 10, 2025

You can ask Aime